Small inpatient trial finds PP-01 eased cannabis withdrawal symptoms
Proof-of-concept trial of PP-01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder.
AI Summary
This Phase 1b/2a randomized, double-blind, placebo-controlled crossover study examined whether PP-01—a combination of the cannabinoid drug nabilone and gabapentin—could reduce cannabis withdrawal symptoms in 14 adults with moderate to severe cannabis use disorder. Participants were monitored during a 5-night inpatient stay after receiving PP-01 or placebo.
Compared with placebo, PP-01 significantly reduced both the severity and bothersomeness of withdrawal symptoms within hours of the first dose. Participants also reported improved sleep quality and reduced cannabis cravings, while objective withdrawal measures improved as well. PP-01 was well tolerated in this study: reported adverse events were mild, and there were no serious adverse events. However, this was a small, short proof-of-concept trial, so the abstract cannot establish whether PP-01 supports long-term abstinence, prevents relapse, or works broadly outside an inpatient setting. This is an abstract-based summary, not a review of the full text.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Addiction research papers you might find interesting.
U.S. survey finds distinct patterns of frequent alcohol, nicotine, and…
Treatment records show a sharp rise in stimulant use in Oman, 2019–2024
An 18-month cohort found adverse outcomes were infrequent, but long-term risks…
Explore More Research
Stay informed about the latest cannabis science.